Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,898.00 GBX | +0.35% | -3.33% | +12.25% |
Sep. 18 | European Equities Close Lower in Wednesday Trading; EU, Euro Area Inflation Declines in August | MT |
Sep. 18 | AstraZeneca Says US FDA Approves Fasenra for Rare Vasculitis Treatment | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B | |||||
Cost of Goods Sold, Total | 4.85B | 5.25B | 9.8B | 8.62B | 8.04B | |||||
Gross Profit | 19.54B | 21.37B | 27.62B | 35.73B | 37.77B | |||||
Selling General & Admin Expenses, Total | 11.38B | 11.59B | 14.46B | 17.47B | 18.02B | |||||
R&D Expenses | 5.35B | 6.12B | 8.55B | 9.53B | 10.3B | |||||
Other Operating Expenses | -319M | -486M | -207M | -231M | -987M | |||||
Other Operating Expenses, Total | 16.41B | 17.22B | 22.81B | 26.77B | 27.34B | |||||
Operating Income | 3.13B | 4.15B | 4.81B | 8.96B | 10.43B | |||||
Interest Expense, Total | -780M | -738M | -776M | -917M | -1.22B | |||||
Interest And Investment Income | 145M | 77M | 43M | 81M | 301M | |||||
Net Interest Expenses | -635M | -661M | -733M | -836M | -918M | |||||
Income (Loss) On Equity Invest. | -116M | -27M | -64M | -5M | -12M | |||||
Currency Exchange Gains (Loss) | -30M | -34M | -20M | -16M | -34M | |||||
Other Non Operating Income (Expenses) | -542M | -487M | -478M | -370M | -292M | |||||
EBT, Excl. Unusual Items | 1.8B | 2.94B | 3.52B | 7.74B | 9.18B | |||||
Restructuring Charges | -347M | -251M | -1.28B | -717M | -467M | |||||
Merger & Related Restructuring Charges | - | - | -2.44B | -3.57B | -137M | |||||
Gain (Loss) On Sale Of Investments | - | - | 776M | - | - | |||||
Gain (Loss) On Sale Of Assets | 1.22B | 1.06B | 509M | 216M | 292M | |||||
Asset Writedown | -1.04B | -252M | -2.07B | -241M | -434M | |||||
Legal Settlements | -610M | 9M | -48M | -789M | -1.01B | |||||
Other Unusual Items | 516M | 416M | 774M | -133M | -520M | |||||
EBT, Incl. Unusual Items | 1.55B | 3.92B | -265M | 2.5B | 6.9B | |||||
Income Tax Expense | 321M | 772M | -380M | -792M | 938M | |||||
Earnings From Continuing Operations | 1.23B | 3.14B | 115M | 3.29B | 5.96B | |||||
Net Income to Company | 1.23B | 3.14B | 115M | 3.29B | 5.96B | |||||
Minority Interest | 108M | 52M | -3M | -5M | -6M | |||||
Net Income - (IS) | 1.34B | 3.2B | 112M | 3.29B | 5.96B | |||||
Net Income to Common Incl Extra Items | 1.34B | 3.2B | 112M | 3.29B | 5.96B | |||||
Net Income to Common Excl. Extra Items | 1.34B | 3.2B | 112M | 3.29B | 5.96B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.03 | 2.44 | 0.08 | 2.12 | 3.84 | |||||
Basic EPS - Continuing Operations | 1.03 | 2.44 | 0.08 | 2.12 | 3.84 | |||||
Basic Weighted Average Shares Outstanding | 1.3B | 1.31B | 1.42B | 1.55B | 1.55B | |||||
Net EPS - Diluted | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | |||||
Diluted EPS - Continuing Operations | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | |||||
Diluted Weighted Average Shares Outstanding | 1.3B | 1.31B | 1.43B | 1.56B | 1.56B | |||||
Normalized Basic EPS | 0.95 | 1.44 | 1.55 | 3.12 | 3.7 | |||||
Normalized Diluted EPS | 0.95 | 1.44 | 1.54 | 3.1 | 3.67 | |||||
Dividend Per Share | 2.8 | 2.8 | 2.87 | 2.9 | 2.9 | |||||
Payout Ratio | 269.06 | 111.76 | 3.44K | 132.72 | 75.25 | |||||
American Depositary Receipts Ratio (ADR) | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | |||||
Supplemental Items | ||||||||||
EBITDA | 5.65B | 6.76B | 8.62B | 13.9B | 15.01B | |||||
EBITA | 4.99B | 6.08B | 7.89B | 13.04B | 14.28B | |||||
EBIT | 3.13B | 4.15B | 4.81B | 8.96B | 10.43B | |||||
EBITDAR | 5.64B | 6.76B | 8.62B | - | - | |||||
Total Revenues (As Reported) | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B | |||||
Effective Tax Rate - (Ratio) | 20.74 | 19.71 | 143.4 | -31.67 | 13.6 | |||||
Total Current Taxes | 1.31B | 971M | 1.2B | 1.64B | 2.44B | |||||
Total Deferred Taxes | -988M | -199M | -1.58B | -2.43B | -1.51B | |||||
Normalized Net Income | 1.23B | 1.89B | 2.2B | 4.83B | 5.73B | |||||
Interest on Long-Term Debt | 22M | 21M | 22M | 24M | 33M | |||||
Non-Cash Pension Expense | 22M | 16M | 38M | 42M | 37M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 339M | 399M | 446M | 534M | 539M | |||||
Research And Development Expense From Footnotes | 6.13B | 6.05B | 9.82B | 9.84B | 11.02B | |||||
Net Rental Expense, Total | -2M | -4M | 6M | - | - | |||||
Imputed Operating Lease Interest Expense | -603K | -1.09M | 1.33M | - | - | |||||
Imputed Operating Lease Depreciation | -1.4M | -2.91M | 4.67M | - | - | |||||
Stock-Based Comp., Other (Total) | 259M | 277M | 615M | 619M | 579M | |||||
Total Stock-Based Compensation | 259M | 277M | 615M | 619M | 579M |